Navigation Links
Pharmasset Reports Fiscal Year End 2009 Financial Results
Date:11/25/2009

2009.

Total costs and expenses for the fiscal year ended September 30, 2009 were $65.9 million, of which $26.7 million was associated with clevudine. This compares to $56.3 million for the same period in 2008, of which $26.5 million was related to clevudine. The increased operating expenses for fiscal year 2009 were primarily the result of an increase in preclinical and clinical trial expenses for PSI-7851 for the treatment of chronic HCV infection.

Pharmasset reported a net loss attributable to common stockholders of $55.6 million, or $2.10 per share, as compared to a net loss attributable to common stockholders of $54.7 million, or $2.51 per share for the same period in 2008.

Calendar Year 2010 Anticipated Milestones

-- Roche anticipates completion of enrollment for Cohort 2 in the RG7128 phase 2b trial by the end of first quarter of 2010

-- We expect to initiate phase 2a trial with PSI-7851 in the first quarter of 2010 with interim data in the third quarter 2010

-- Roche expects to initiate INFORM-2 in first quarter 2010

-- We expect to file an IND for PSI-938 in first quarter of 2010

-- Roche expects to initiate longer duration, phase 2b studies with RG7128 in combination with pegylated interferon and ribavirin in first half of 2010

-- Roche expects to initiate longer duration INFORM studies to investigate SVR in the first half of 2010

-- We expect to initiate phase 1 trial with PSI-938 in first quarter of 2010 with interim data in the third quarter 2010

-- Roche expects to initiate a phase 2 study in genotype 2 and 3 HCV patients with RG7128 in the second half of 2010

-- We expect to file an IND for PSI-879 in fourth quarter of 2010

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infec
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
4. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
5. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
6. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Pharmasset Reports Fiscal Year End 2008 Financial Results
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, ... and technologies must be able to protect ... (IP). (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ... nature of the Medical Device Industry, it ... industry sectors of cases involving IP infringement. ...
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and ... "TEN", Noble Financial Capital Markets, Tenth Annual Equity ... a corporate presentation to prospective corporate partners and ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 /PRNewswire/ ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ... Summary,Although the past decade has ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... S.C., Sept. 9 At approximately 3:21,PM ... Chairman and Founder of,CureHIV.us, agreed to act ... Global,Humanceuticals, Inc,s., new extremely effective, safe and ... non-government, U.S.,and foreign institutions, organizations, and corporations, ...
... Effective Antibiotics Against ,Superbugs, BOSTON, Sept. 6 ... may have discovered the path,toward developing better drugs ... resistance to common antibiotics. The,researchers have discovered a ... opens to door to new avenues of research., ...
Cached Medicine Technology:Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug 2Boston University Biomedical Engineers Find Chink in Bacteria's Armor 2Boston University Biomedical Engineers Find Chink in Bacteria's Armor 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... July 24, 2009 -- Half of all Americans will be ... number two killer in the United States. One of the ... to the National Cancer Institute, 192,370 women will be diagnosed ... will die from the disease this year alone. One ...
... , , , SAN ... G. Komen for the Cure, one of over 100 Affiliates nationwide dedicated ... over $1.6 million dollars to support Bay Area breast health education and ... The Komen San Francisco Bay Area Affiliate,s local fundraising ...
... July 24 Yesterday, the U.S. House of Representatives ... prohibits HHS (Health and Human Services) funding for programs which distribute ... such as HIV and hepatitis. The amendment reads as follows: , ... bill (before the short title), insert the following: Sec.___. None ...
... , , FARMINGTON ... provider of aesthetic services in the U.S., announced the launch of ... the training of current and new technicians, clinic managers and corporate ... best in class service and enhance the customer experience. ...
... , COLUMBIA, S.C., July 24 UCI ... Wells, Jr., the former Executive Vice-President of Finance, Chief Financial ... pled guilty on July 23, 2009 in federal court to ... filed with the Securities and Exchange Commission. On the ...
... Taking samples from accident patients may offer a medical ... -- Testing the blood-alcohol level of trauma patients could ... complications from drinking issues, a new study says. ... leaving medical personnel in the dark about potentially serious ...
Cached Medicine News:Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 2Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 3Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 4Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 5Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.2 Million This Year to Community Outreach Programs 2Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.2 Million This Year to Community Outreach Programs 3Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.2 Million This Year to Community Outreach Programs 4Health News:American Laser Centers Announces Launch of 'ALC University' 2Health News:UCI Medical Affiliates, Inc.'s Internal Investigation Leads to Former Executive Officer Pleading Guilty to Criminal Charges 2Health News:Alcohol and Trauma: Blood Test Gets to the Truth 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: